GUIDELINE RECOMMENDED PHARMACOLOGICAL MANAGEMENT OF PATIENTS WITH ATRIAL FIBRILLATION, AT A TERTIARY CARE CARDIAC CENTRE, KARACHI PAKISTAN“ARE WE PRACTICING WHAT WE TEACH”?
DOI:
https://doi.org/10.47144/phj.v46i4.703Keywords:
Atrial fibrillation, Valvular Heart Disease, Thromboembolism, Guidelines, Rate controlling therapy, WarfarinAbstract
Objective: To observe the practice of guideline recommend, pharmacologicalmanagement of patients with Atrial fibrillation (AF), at tertiary care cardiac center.
Methodology: It was a descriptive cross-sectional study of six months duration
conducted in National Institute of Cardiovascular Diseases Karachi (NICVD) from
April to October 2007.Two hundred indoor patients with AF were evaluated. Data
was recorded and analyzed by SPSS version 16.
Results: Majority of the patients with AF (76%), were <65 years of age. 46.5 % of
patients had valvular heart disease. Rate controlling drugs were prescribed in
180 (90%) patients. Total of 88 (44%) patients received beta blocker, 83 (41.5%)
patients received digoxin. In 19% of the patients with high risk for
thromboemoblism, neither Aspirin nor Warfarin was prescribed. In 14 % of low
risk patients, both Aspirin and Warfarin were advised.
Conclusion: In contrast to western studies majority of our patients with AF were
younger and almost half of them had valvular heart disease. Reasonable number
of our patients with AF received guideline recommended pharmacological rate
controlling therapy. Preventive pharmacological strategy for thromboembolic
events was highly un-acceptable.
Downloads
Downloads
How to Cite
Issue
Section
License
When an article is accepted for publication in the print format, the author will be required to transfer exclusive copyright to the PHJ and retain the rights to use and share their published article with others. However, re-submission of the full article or any part for publication by a third party would require prior permission of the PHJ.
Online publication will allow the author to retain the copyright and share the article under the agreement described in the licensing rights with creative commons, with appropriate attribution to PHJ. Creative Commons attribution license CC BY 4.0 is applied to articles published in PHJ https://creativecommons.org/licenses/by/4.0/